Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT

GoodsAward procedure without prior publication of a call for competition

Awarded value£3,000,000published contract · exc. VAT

Awarded 30 Jun 2022no call for competition

Awarded to Advanced Accelerator Applications (UK and Ireland) Ltd2 awards

What is being bought

Published requirement description

Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT

CPV: Medical equipments, pharmaceuticals and personal care products

single lot · no lot value published

Lot #1Awarded

Delivery: Northern Ireland · Belfast Health and Social Care Trust

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 8 Jun 2022, 08:09 BST
Last source update: 30 Jun 2022, 14:44 BST
Authority reference: DAC10464
FTS notice number: 2022/S 000-017908
Classification (CPV): Medical equipments, pharmaceuticals and personal care products
Delivery area: Northern Ireland (UKN)
Official registry OCID: ocds-h6vhtk-034401 Find a Tender

Why no open competition: The works, supplies or services can be provided only by a particular economic operator due to protection of exclusive rights, including intellectual property rights
Published justification: No other reasonable alternative or substitute exists for this procurement and the absence of competition is not a result of the artificial narrowing of the parameters of the procurement. Lutetium (177Lu) oxodetreotide (Lutathera) is a licensed radiopharmaceutical for the treatment of unresectable or metastatic, progressive, well-differentiated somatostatin receptor positive gastro-entero-pancreatic neuroendocrine (GEP) tumours in adults. The supplier, Advanced Accelerator Applications (AAA), holds the unique patent and licence for this product. This is the only licenced Peptide Receptor Radionuclide Therapy (PRRT) in Europe

Published awards, contracts and bid statistics, not a forecast

Awards 2

Awarded value £3,000,0001 contract exc. VAT · 1 repeated publication of the same award counted once

Bids received 1

Contracts signed 2latest 30 Jun 2022

Awarded to	Value	Date	Status
Advanced Accelerator Applications (UK and Ireland) Ltd	£3,000,000 †same award published again · counted once	—	Awarded
Advanced Accelerator Applications (UK and Ireland) Ltd	£3,000,000 †	—	Awarded

Contracts

Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT · Advanced Accelerator Applications (UK and Ireland) Ltd
Signed
30 Jun 2022
Value
£3,000,000
Status
active
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT · Advanced Accelerator Applications (UK and Ireland) Ltd
Signed
8 Jun 2022
Value
£3,000,000
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

Contracting authorityCentral GovernmentBody governed by public lawHealth LISBURN ROAD, BELFAST, Northern Ireland, BT97ABContact name, email

1 commercial party on the notice

Advanced Accelerator Applications (UK & Ireland) LtdAwarded supplier Edison House, 223-231 Old Marylebone Road, London, London, NW1 1QT

Official links; attachments are not copied

No document links were published on the notice.